A pilot, randomized clinical trial of bedtime doses of prazosin versus placebo in suicidal posttraumatic stress disorder patients with nightmares

William Vaughn McCall, Anilkumar Pillai, Doug Case, Laryssa McCloud, Tiffany Nolla, Fallon Branch, Nagy A. Youssef, Jason Moraczewski, Liniya Tauhidul, Chirayu D. Pandya, Peter B. Rosenquist

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Purpose/Background Observational studies show an association between nightmares and suicide. Prazosin is proposed as a nightmare treatment. This pilot, randomized clinical trial tested whether treatment of nightmares with prazosin would reduce suicidal ideas in suicidal posttraumatic stress disorder (PTSD) patients. Methods/Procedures Twenty adult, suicidal PTSD patients with nightmares were blindly and randomly assigned 1:1 to escalating doses of prazosin versus placebo at bedtime only for 8 weeks. All participants had comorbid mood disorders and received stable doses of mood disorder medication. Outcomes of interest were measured weekly and included severity of suicidal ideation, nightmares, PTSD, insomnia, and depression. Longitudinal mixed-effects models assessed change in outcomes over time. Findings/Results All psychometric measures improved over 8 weeks. However, nighttime measures of nightmares and insomnia showed significantly less improvement in the prazosin group, whereas there was no significant change in daytime measures of suicidal ideation and daytime-only PTSD symptoms. Two patients required emergency psychiatric hospitalization, but there were no suicide attempts and no deaths. Implications/Conclusions This study confirmed an effect of nighttime-only prazosin on nighttime symptoms of insomnia and nightmares in suicidal PTSD patients who are experiencing nightmares. Surprisingly, the effect was in the direction opposite of what we expected. Furthermore, prazosin showed no signal on daytime measures including suicidal ideation. The results do not support a larger study of nighttime-only prazosin in suicidal PTSD patients but leave open the possibility of benefit from daytime administration of prazosin.

Original languageEnglish
Pages (from-to)618-621
Number of pages4
JournalJournal of Clinical Psychopharmacology
Issue number6
StatePublished - Dec 1 2018

Bibliographical note

Funding Information:
From the *Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA; †Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC; and ‡Medical Laboratory, Imaging, and Radiologic Sciences Department, College of Allied Health, Augusta University, Augusta, GA. Received March 21, 2018; accepted after revision August 15, 2018. Reprints: William Vaughn McCall, MD, MS, Medical College of Georgia, Augusta University, 997 St, Sebastian Way, Augusta, GA 30912 (e‐mail: wmccall@augusta.edu). Grant Support: American Foundation for Suicide Prevention DIG-0-087-13. ClinicalTrials.gov Identifier: NCT02199652. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0271-0749 DOI: 10.1097/JCP.0000000000000968

Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.


  • nightmares
  • posttraumatic stress disorder
  • prazosin
  • suicide

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'A pilot, randomized clinical trial of bedtime doses of prazosin versus placebo in suicidal posttraumatic stress disorder patients with nightmares'. Together they form a unique fingerprint.

Cite this